The following data were collected from the patients’ medical records at the start of remission induction therapy (i.e., baseline): demographic information (age, sex), disease status (newly diagnosed or relapsed), ANCA status (anti-proteinase 3 [PR3] positive or anti-myeloperoxidase [MPO] positive), type of vasculitis (MPA or GPA), the type of remission induction therapy (RTX or CY), and the number of days from baseline to the initiation of avacopan (in the avacopan group only). This evidence concerns the gene MPO and microscopic polyangiitis.